Neuralace Medical Announces First Patients Enrolled in the AT-PDN Study Evaluating Axon Therapy® for the Treatment of Painful Diabetic Neuropathy
Neuralace Medical intends to utilize the output of the AT-PDN multicenter study to support the FDA 510(k) application for Axon Therapy label expansion to include Treatment for Painful Diabetic Neuropathy SAN DIEGO, Jan. 9, 2023 /PRNewswire/ — Neuralace Medical, Inc., a commercial-stage…
Comments Off on Neuralace Medical Announces First Patients Enrolled in the AT-PDN Study Evaluating Axon Therapy® for the Treatment of Painful Diabetic Neuropathy